Results for dealkylation translation from English to Maltese

22 dealkylation of buprenorphine.
22 metaboliżmu u eliminazzjoni:

n-dealkylation of the pyrrolidine nitrogen.
n-dealkylation ta’ pyrrolidine nitrogen.

masitinib is metabolised predominantly by n-dealkylation.
masitinib huwa metabolizzat primarjament minn n-dealkylation.

n-dealkylation and/ or hydroxylation to yield:
n- dialkajlazzjoni u/ jew idroxilazzjoni biex jipproduċi:

another metabolic pathway of risperidone is n-dealkylation.
mogħdija metabolika oħra ta ’ risperidone hija n- dealkylation.

the main metabolic pathway of osimertinib was oxidation and dealkylation.
il-passaġġ metaboliku ewlieni ta' osimertinib kienu l-ossidazzjoni u d-dejalkilazzjoni.

firocoxib is metabolised predominantly by dealkylation and glucuronidation in the liver.
il-firocoxib huwa metabolizzat l-aktar bil-dejalkilazzjoni u glukoronidazzjoni fil-fwied.

additional minor metabolic pathways consist of n-dealkylation and hydrolysis.
passaġġi metaboliċi oħra huma n-dealkilazzjoni u idrolisi.

clinical data confirm that cyp3a4 is responsible for the n- dealkylation of buprenorphine.
dejta klinika tikkonferma li cyp3a4 hi responsabbli għal n-dealkylation ta’ buprenorphine.

in vitro results indicate that different cyp isoforms are able to catalyse the n-dealkylation of rotigotine.
riżultati in vitro jindikaw li isoformi differenti tas- cyp jistgħu jikkatalizzaw l-n-dealkylation ta’ rotigotine.

fourteen primary pathways have been identified of which o-demethylation and n-dealkylation are the most important.
erbatax il-mogħdija primarja ġew identifikati mil-liema o-demethylation u n-dealkylation huma l-aktar importanti.

the major biotransformation pathways are oxidative n-dealkylation, hydroxylation of norbornane ring, and s-oxidation.
ir-rotot ewlenin ta’ bijotransformazzjoni huma n-dealkilazzjoni ossidattiva, idroksilazzjoni taċ-ċirku norbornane, u ossidazzjoni-s.

metabolism of tasimelteon consists primarily of oxidation at multiple sites and oxidative dealkylation resulting in opening of the dihydrofuran ring followed by further oxidation to give a carboxylic acid.
il-metaboliżu ta' tasimelteon jikkonsisti primarjament minn ossidazzjoni f’diversi postijiet u dealkalizazzjoni ossidattiva li jirriżultaw fil-ftuħ taċ-ċirku tad-dihydrofuran segwit minn iktar ossidazzjoni biex jagħti aċidu karbossiliku.

aromatic hydrocarbons, c7-8, dealkylation products, distillation residues; low boiling point naphtha — unspecified
idrokarburi aromatiċi, c7-8, prodotti ta' dealkilazzjoni, residwi ta' distillazzjoni; nafta b'punt baxx ta' togħlija – mhux speċifikata

aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and n-dealkylation.
aripiprazole tiġi metabolizzata b’mod qawwi mill-fwied bi tlett metodi ta’ biotransformazzjoni: deidroġinazzjoni, idroksilazzjoni u n-di-alkajlazzjoni.

buprenorphine, when taken orally, undergoes first-pass metabolism with n-dealkylation and glucuroconjugation in the small intestine and the liver.
buprenorphine, meta jittieħed b’ mod orali, jgħaddi minn metaboliżmu first pass b ’ n - dealkalizazzjoni u glukurkonjugazzjoni fil- musrana ż- żgħira u l- fwied.

the three main metabolic routes are as follows: monohydroxylation in the dihydrobenzofuran ring; dihydrobenzofuran ring opening and n-dealkylation of the pyrrolidine nitrogen.
monohydroxylation fid- dihydrobenzofuran ring il- ftuħ tad- dihydrobenzofuran ring u n- dealkylation ta ’ pyrrolidine nitrogen.

the primary metabolic pathways in humans were oxidation of the piperidine ring to crizotinib lactam and o-dealkylation, with subsequent phase 2 conjugation of o-dealkylated metabolites.
il-mogħdijiet metaboliċi primarji fil-bnedmin kienu l-ossidazzjoni tal-piperidine ring għal crizotinib lactam u o-dealkilazzjoni, bil-konjugazzjoni sussegwenti tal-fażi 2 ta’ metaboliti o- dealkilati.

four metabolic pathways have been identified in vivo, none of which accounted for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
Ġew identifikati erba’ mogħdijiet metaboliċi in vivo, li l-ebda waħda minnhom ma kienet responsabbli għal iktar minn 10 % tad-doża: dealkilazzjoni, idroksilazzjoni, deidroġenazzjoni, u xizzjoni tal-benzisoxazole.

four metabolic pathways have been identified in vivo, none of which accounted for more than 6.5% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
Ġew identifikati erba’ mogħdijiet metaboliċi in vivo, li l-ebda waħda minnhom ma kienet twassal għal iktar minn 6.5% tad-doża: dealkilazzjoni, idroksilazzjoni, deidroġenazzjoni, u xizzjoni tal-benzisoxazole.